Oncology Contract Research Organization (CRO) - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The oncology contract research organization market size is projected to expand from USD 23.08 billion in 2025 and USD 24.62 billion in 2026 to USD 35.13 billion by 2031, registering a CAGR of 7.36% between 2026 to 2031. This report is Segmented by Clinical Phase (Pre-Clinical, Phase I and More), Service Type (Discovery & Translational Research Services and More), Indication (Solid Tumors, Hematologic Malignancies, and More), End Users (Pharmaceuticals and Biopharmaceutical Companies and More), and Geography (North America, Europe, Asia-Pacific, and More). Market Forecasts are in Value (USD).

Global Oncology Contract Research Organization (CRO) Market Trends and Insights

Precision-Oncology Pipelines Boosting Outsourcing Demand

Molecularly targeted assets such as antibody-drug conjugates, CAR-T therapies, and bispecific T-cell engagers require narrow biomarker-based cohorts that few sponsors can recruit alone. The FDA cleared 16 precision-oncology medicines in 2024, and more than 1,200 targeted agents were in the global pipeline by early 2025, sustaining demand for CROs with translational research, companion diagnostic, and decentralized-site capabilities. Sponsors increasingly choose vendors that verify biomarkers during pre-clinical work, execute adaptive dose-finding designs, and maintain relationships with diagnostics developers. North America and Europe dominate current activity thanks to mature regulatory pathways, but Asia-Pacific labs are scaling fast to support regional trials. Given every new target spawns numerous combination and resistance-mechanism studies, the long-term pull on the oncology contract research organization (CRO) market remains strong.

Rising Use of Complex Adaptive Trial Designs

Basket, umbrella, and seamless Phase I/II protocols let sponsors refine dose and cohort composition in real time, cutting both sample size and development cycles. The FDA released draft guidance on master protocols in 2024, while the EMA followed with recommendations in 2025, giving sponsors clearer rules for adaptive oncology designs. Adaptive execution demands sophisticated biostatistics, continuous data review, and flexible budgets, pushing work to CROs that already own these capabilities. IQVIA applied its Decentralized Trials platform to 12 adaptive oncology studies during 2025, demonstrating commercial traction. Most uptake centers on the United States, Europe, and Japan, where regulatory acceptance and early-stage pipelines align.

Scarcity of Oncology-Savvy Investigators in Mature Regions

High trial density in the United States and Western Europe has overtaken investigator supply. An ACRP survey reported 62% of U.S. oncology sites faced capacity constraints in 2024, lengthening contract-signature cycles to 68 days, up from 45 days in 2022. Sub-specialty fields like pediatric solid tumors feel the pinch most. Sponsors and CROs are widening site networks into Eastern Europe and Latin America to ease pressure, but those regions often lack the lab infrastructure necessary for complex biomarker assays. Without new investigator training pipelines, bottlenecks could moderate enrollment speed and temper growth in the oncology contract research organization (CRO) market.

Other drivers and restraints analyzed in the detailed report include:

• Scale-Out of Decentralized / Hybrid Oncology Trials
• AI-Enabled Patient-Matching & Site-Selection Efficiencies
• Sponsor Concerns Over Cross-Border Data Security

Segment Analysis

Phase III programs captured 39.5% of 2025 revenue, reflecting many late-stage immunotherapy and antibody-drug conjugate studies that still rely on large, randomized survival endpoints. However, the oncology contract research organization (CRO) market size associated with Phase I work is set to rise fastest at a 7.89% CAGR to 2031 as precision assets demand molecularly defined dose-escalation cohorts. Seamless Phase I/II designs, endorsed by FDA and EMA guidance, let sponsors jump directly from safety to efficacy arms once a threshold is met. This evolution favors CROs with early-phase units skilled in adaptive enrollment and rapid biomarker turnaround.

Growth in pre-clinical outsourcing also supports early-phase momentum. Sponsors leverage integrated discovery-to-IND packages that combine target validation, translational research, and GLP toxicology, cutting months off IND submission timelines. The near-shoring wave tightened U.S. vivarium supply yet spurred capital projects by Charles River and Labcorp that will unlock fresh capacity in 2026. Together, these developments anchor long-run expansion of the oncology contract research organization (CRO) market in first-in-human studies.

Clinical services delivered 30% of revenue in 2025, driven by site management, data monitoring, and patient recruitment across global networks. Still, pre-clinical and discovery activities are pacing ahead, each forecast at 7.5% CAGR through 2031, as drug makers value single-vendor support that validates targets, produces animal efficacy data, and handles IND-enabling safety assays. WuXi AppTec’s platform shepherded 45 oncology programs from discovery to Phase I in 2025, illustrating the pull toward integrated offerings. Central laboratory and biomarker work captured notable share of 2025 revenue and continues to expand as regulators insist on prospective biomarker-development plans for targeted drugs. Large sample-processing players processed tens of millions of oncology specimens last year and have built genomic sequencing and flow-cytometry suites to keep ahead of demand. Real-world evidence services also grow, powered by claims and EHR aggregation tools that feed payer submission packages. These complementary capabilities help full-service vendors cross-sell, boosting their oncology contract research organization (CRO) market share.

Complete Report Scope:

• By Clinical Phase
  • Pre-clinical
  • Phase I
  • Phase II
  • Phase III
  • Phase IV
• By Service Type
  • Discovery & Translational Research Services
  • Pre-clinical Services
  • Clinical Services
  • Central Laboratory & Biomarker Services
  • Real-World Evidence & Late-Phase
  • Others
• By Indication
  • Solid Tumors
  • Hematologic Malignancies
  • Rare & Pediatric Cancers
• By End Users
  • Pharmaceuticals and Biopharmaceutical companies
  • Academic & Research Institutes
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America commanded 47.78% of 2025 revenue, supported by dense investigator networks, proximity to the FDA, and reimbursement models that encourage domestic pivotal trials. The United States recorded more than 1,800 oncology trial starts in 2024, equal to around 40% of global activity. Canada and Mexico add incremental volume, offering ICH-aligned regulations and cost-efficient sites that keep studies within the region. Near-shoring of toxicology work under the BIOSECURE Act pushed even more early-phase dollars into U.S. and European hubs, straining capacity in mid-2025 but promising long-term upside for local vendors.

Asia-Pacific is the fastest-growing geography, projected at an 8% CAGR through 2031. China’s NMPA approved 23 oncology agents in 2024 and continues to permit conditional marketing while post-approval studies run in parallel, accelerating timelines. India halved median clinical-trial review time to nine months in 2024, and its vast treatment-naïve patient pool makes it highly attractive for enrollment-intensive Phase III work. Japan and South Korea bring high-quality data sets and synchronized submissions with the FDA and EMA, while Australia’s fast-track early-phase schemes and R&D tax rebates pull first-in-human work southward.

Europe held significant share of revenue in 2025, anchored by Germany, the United Kingdom, and France. The EU Clinical Trials Regulation, fully operational in 2025, simplified multi-country approvals, and the EMA PRIME scheme granted priority status to 14 oncology projects last year. Emerging regions round out the map: the Gulf Cooperation Council invests in oncology research hubs, South Africa provides diverse genetic pools, and Brazil and Argentina supply cost-efficient sites paired with experienced investigators. Although smaller today, these regions offer future enrollment relief as mature markets saturate.

List of Companies Covered in this Report:

• Altasciences
• BioAgilytix Labs
• Charles River
• Eurofins
• Frontage Laboratories
• Genscript Biotech
• ICON
• IQVIA
• Jubilant Biosys
• KBI Biopharma
• LabCorp
• Lonza Bioscience Solutions
• Medpace Holdings
• Parexel International
• PPD (Thermo Fisher Scientific)
• Rentschler Biopharma
• Samsung Biologics CRO Services
• SGS
• Syneos Health
• WuXi App Tec

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support